
Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
Abbott's Humira (adalimumab) had been approved by the food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis...
Abbott's Humira (adalimumab) has been approved by the Food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis.
JVA joins other indications including chronic plaque psoriasis, rheumatoid arthritis in adults, and Crohn's disease.






